A phase II multicenter trial employing a single-arm, open-label design evaluated Enlonstobart, an innovative PD-1 inhibitor, in patients with PD-L1-positive cervical cancer with disease progression or intolerance to initial platinum-based chemotherapy. This evidence concerns the gene CD274 and cervical cancer.